TOT BIOPHARM International Co. Ltd. (HK:1875) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TOT BIOPHARM International Co. Ltd. has reported a significant year-on-year revenue increase of 59% for the first half of 2024, driven by robust sales of their core product Pusintin and a 144% increase in their CDMO/CMO business. The company has successfully transitioned from a loss to a profit, with net earnings of RMB31,559 thousand. Additionally, the firm has strengthened its position in the biopharmaceutical CDMO market, securing 20 new projects and increasing its order backlog by 104%.
For further insights into HK:1875 stock, check out TipRanks’ Stock Analysis page.